---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-023796"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2022-02-15T23:59:59+00:00"
generated_at: "2026-06-27T07:52:07.023417+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CVRx posts Q4 revenue $3.7M (+75% YoY); FY2021 revenue $13.0M; guides FY2022 rev $20-23M

## Summary
- Q4 2021 revenue $3.7M, up 75% YoY; US HF revenue $2.7M, up 345%.
- Full year 2021 revenue $13.0M, up 115% YoY; net loss $43.1M ($4.16 per share).
- Guides FY2022 total revenue $20-23M; Q1 2022 revenue $3.6-4.0M; gross margin 74-76%.
- Received FDA approval for new IPG in Dec 2021; expects MRI labeling and new programmer approvals in H1 2022.
- Fully repaid $20M loan in Nov 2021; cash $142.1M at year-end.

## SEC filing metadata
- accession: 0001104659-22-023796
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2022-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465922023796/0001104659-22-023796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465922023796/tm226604d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-023796
- JSON: https://secwatch.observer/filing/0001104659-22-023796.json
- Plain text: https://secwatch.observer/filing/0001104659-22-023796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.